CU6 — Clarity Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$695.59m
- AU$517.34m
Australia's Clarity Pharmaceuticals rises on cancer product progress
Australia's healthcare stocks drop as Trump plans executive order to cut prescription drug prices
Australia's Clarity Pharmaceuticals drops; Jefferies cuts PT on downbeat outlook
Brief: Clarity Signs High-Volume Commercial-Scale Copper-64 Supply Agreement With Nusano
Australia's Clarity Pharma gains on tax break to develop cancer platform
Brief: Clarity Pharmaceuticals Signs Commercial-Scale Copper-64 Supply Agreement
Brief: Secure Trial Update First Patient Treated In The Phase Ii Cohort Expansion
Australia's Clarity Pharmaceutical gains on reporting first prostate cancer treatment
Clarity Pharmaceuticals gains on supply agreement with University of Queensland
Australia's Clarity Pharmaceuticals hits 10-month low on bigger HY loss
Brief: Clarity Pharmaceuticals Posts HY Loss From Ordinary Activities After Tax A$23.582 Million
Brief: Clarity Receives Us FDA Fast Track Designation For The Treatment Of Metastatic Castration-Resistant Prostate Cancer Patients With Cu-67 Sar-Bispsma
Brief: Clarity Pharmaceuticals Gets US FDA Fast Track Designation
Australia's Clarity Pharmaceuticals surges on FDA fast track status for prostate cancer drug
Brief: Clarity Pharmaceuticals Gets US FDA Fast Track Designation For Cu- 64 Sar-Bispsma
Australia's Clarity Pharmaceuticals soars on new cancer treatment
Brief: Clarity Pharmaceuticals And Nucleus Radiopharma Sign Master Services Agreement
Australia's Clarity Pharma jumps on deal with US co
Amplify Trial Patient Recruitment To Commence In Early 2025